<PAPER>
  <mode2 name="16880202_arathi" hasDoc="yes" version="1258"/>
  <TITLE>
    <s sid="1">Aspirin Induces Apoptosis through the Inhibition of Proteasome Function*<CoreSc1 atype="GSC" type="Con" conceptID="Con1" novelty="None" advantage="None"/></s>
  </TITLE>
  <ABSTRACT>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-1">
      <s sid="2">Aspirin and other nonsteroidal anti-inflammatory drugs inhibit cell proliferation and induce apoptosis in various cancer cell lines, which is considered to be an important mechanism for their anti-tumor activity and prevention of carcinogenesis.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac1" novelty="None" advantage="None"/></s>
      <s sid="3">However, the molecular mechanisms through which these compounds induce apoptosis are not well understood.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot1" novelty="None" advantage="None"/></s>
      <s sid="4">Here we have found that aspirin treatment of the mouse Neuro 2a cells impaired the proteasome function and caused severe mitochondrial abnormalities.<CoreSc1 atype="GSC" type="Res" conceptID="Res1" novelty="None" advantage="None"/></s>
      <s sid="5">Treatment with aspirin lead to a dose- and time-dependent decrease in proteasome activity and an increase in the accumulation of ubiquitylated proteins in the cells, which correlated with its effect on cell death.<CoreSc1 atype="GSC" type="Res" conceptID="Res2" novelty="None" advantage="None"/></s>
      <s sid="6">Aspirin exposure also resulted in an increase in the half-life of pd1EGFP, a model substrate of proteasome, as well as various intracellular substrates like Bax, I&#954;B-&#945;, p53, and p27<sup>kip1</sup>.<CoreSc1 atype="GSC" type="Res" conceptID="Res3" novelty="None" advantage="None"/></s>
      <s sid="7">Aspirin-induced proteasomal malfunction might be responsible, at least in part, for the down-regulation of NF-&#954;B activity and neurite outgrowth.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp1" novelty="None" advantage="None"/></s>
      <s sid="8">Finally, we have shown that aspirin treatment caused changes in the mitochondrial membrane potential, release of cytochrome c from mitochondria, and activation of caspase-9 and -3, which could be because of the proteasomal dysfunction.<CoreSc1 atype="GSC" type="Con" conceptID="Con2" novelty="None" advantage="None"/></s>
    </p>
  </ABSTRACT>
  <BODY>
    <SEC>
      <TITLE/>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-2">
        <s sid="9">Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs)<sup><xref class="xref-fn" href="#fn-1" rid="xref-fn-1-1">3</xref></sup> are well known to inhibit cyclooxygenase activity, the key enzyme in prostaglandin biosynthesis (<xref class="xref-ref" href="#ref-1" rid="xref-ref-1-1">1</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac2" novelty="None" advantage="None"/></s>
        <s sid="10">However, several clinical observations and epidemiological and experimental studies found aspirin and other NSAIDs to be promising anti-cancer agents.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac3" novelty="None" advantage="None"/></s>
        <s sid="11">Prolonged use of NSAIDs has been reported to reduce the risk of cancer of the colon and other gastrointestinal organs as well as cancer of the breast, prostrate, lung, and skin (<xref class="xref-ref" href="#ref-2" rid="xref-ref-2-1">2</xref>-<xref class="xref-ref" href="#ref-6" rid="xref-ref-6-1">6</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac4" novelty="None" advantage="None"/></s>
        <s sid="12">The chemopreventive properties of NSAIDs are the result of their ability to induce apoptosis and are possibly independent of their ability to inhibit cyclooxygenase activity (<xref class="xref-ref" href="#ref-7" rid="xref-ref-7-1">7</xref>-<xref class="xref-ref" href="#ref-14" rid="xref-ref-14-1">14</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac5" novelty="None" advantage="None"/></s>
        <s sid="13">Several mechanisms have been proposed for aspirin-induced apoptosis, including activation of caspases (<xref class="xref-ref" href="#ref-11" rid="xref-ref-11-1">11</xref>-<xref class="xref-ref" href="#ref-14" rid="xref-ref-14-2">14</xref>), down-regulation of NF-&#954;B activity (<xref class="xref-ref" href="#ref-15" rid="xref-ref-15-1">15</xref>-<xref class="xref-ref" href="#ref-17" rid="xref-ref-17-1">17</xref>), activation of ceramide pathway (<xref class="xref-ref" href="#ref-18" rid="xref-ref-18-1">18</xref>), up-regulation of several proapoptotic proteins (<xref class="xref-ref" href="#ref-8" rid="xref-ref-8-1">8</xref>, <xref class="xref-ref" href="#ref-11" rid="xref-ref-11-2">11</xref>, <xref class="xref-ref" href="#ref-14" rid="xref-ref-14-3">14</xref>, <xref class="xref-ref" href="#ref-19" rid="xref-ref-19-1">19</xref>, <xref class="xref-ref" href="#ref-20" rid="xref-ref-20-1">20</xref>), and generation of endoplasmic reticulum (ER) and oxidative stress (<xref class="xref-ref" href="#ref-21" rid="xref-ref-21-1">21</xref>, <xref class="xref-ref" href="#ref-22" rid="xref-ref-22-1">22</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac6" novelty="None" advantage="None"/></s>
        <s sid="14">Aspirin has been found to induce both the extrinsic (the death receptor) and intrinsic (the mitochondrial) pathway of caspase activation (<xref class="xref-ref" href="#ref-10" rid="xref-ref-10-1">10</xref>, <xref class="xref-ref" href="#ref-12" rid="xref-ref-12-1">12</xref>, <xref class="xref-ref" href="#ref-14" rid="xref-ref-14-4">14</xref>), but how it does so is not well understood.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot2" novelty="None" advantage="None"/></s>
        <s sid="15">Aspirin can induce up-regulation of Bax and down-regulation of Bcl-X<sub>L</sub> (<xref class="xref-ref" href="#ref-11" rid="xref-ref-11-3">11</xref>, <xref class="xref-ref" href="#ref-14" rid="xref-ref-14-5">14</xref>, <xref class="xref-ref" href="#ref-19" rid="xref-ref-19-2">19</xref>, <xref class="xref-ref" href="#ref-23" rid="xref-ref-23-1">23</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac7" novelty="None" advantage="None"/></s>
        <s sid="16">The alteration of the ratio of proapoptotic to antiapoptotic molecules could activate the mitochondrial pathway of apoptosis.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac8" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-3"/>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-5">
        <s sid="17">The ubiquitin proteasome system (UPS) is the major extra lysosomal pathway of the cells responsible for the intracellular protein degradation in eukaryotes (<xref class="xref-ref" href="#ref-24" rid="xref-ref-24-1">24</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac9" novelty="None" advantage="None"/></s>
        <s sid="18">A protein to be degraded by this pathway is first covalently attached with multiple molecules of ubiquitin, and then the polyubiquitylated proteins are degraded by the 26 S proteasome.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac10" novelty="None" advantage="None"/></s>
        <s sid="19">The 26 S proteasome is a multicatalytic proteinase complex, which contains 20 S proteasome as its proteolytic core.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj1" novelty="None" advantage="None"/></s>
        <s sid="20">The 20 S proteasome has three different types of proteolytic activities.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac11" novelty="None" advantage="None"/></s>
        <s sid="21">Those are chymotrypsin-like (Tyr or Phe at P1), trypsin-like (Arg or Lys at P1), and post-glutamyl peptidyl hydrolytic-like (Glu at P1) activities.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac12" novelty="None" advantage="None"/></s>
        <s sid="22">The normal function of UPS is necessary for the cell growth by regulating the cell cycle through timely degradation of cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors (<xref class="xref-ref" href="#ref-24" rid="xref-ref-24-2">24</xref>, <xref class="xref-ref" href="#ref-25" rid="xref-ref-25-1">25</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac13" novelty="None" advantage="None"/></s>
        <s sid="23">The proteasome is also associated with many other important functions including degradation of short-lived and misfolded proteins and several transcription factors (<xref class="xref-ref" href="#ref-24" rid="xref-ref-24-3">24</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac14" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-6">
        <s sid="24">Because the UPS is involved in the degradation of many short-lived proteins that are required for cell survival, it is expected that the dysfunction of this pathway will promote cell death.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp2" novelty="None" advantage="None"/></s>
        <s sid="25">In fact, the pharmacological inhibition of proteasome function has been found to induce the dual apoptotic signaling pathways, depending on the cell types and conditions (<xref class="xref-ref" href="#ref-26" rid="xref-ref-26-1">26</xref>-<xref class="xref-ref" href="#ref-32" rid="xref-ref-32-1">32</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac15" novelty="None" advantage="None"/></s>
        <s sid="26">Proteasomal inhibitors also inhibit NF-&#954;B activity, induce oxidative and ER stress response, and activate various stress kinases (<xref class="xref-ref" href="#ref-31" rid="xref-ref-31-1">31</xref>, <xref class="xref-ref" href="#ref-33" rid="xref-ref-33-1">33</xref>, <xref class="xref-ref" href="#ref-34" rid="xref-ref-34-1">34</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac16" novelty="None" advantage="None"/></s>
        <s sid="27">In the present investigation, we demonstrate that aspirin inhibits the proteasome function, induces mitochondrial abnormalities, and activates intrinsic pathway of apoptosis.<CoreSc1 atype="GSC" type="Res" conceptID="Res4" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>EXPERIMENTAL PROCEDURES</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-7">
        <s sid="28">Materials&#8212;Aspirin, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), lactacystin, N-acetylcysteine (NAC), MG132, cycloheximide, proteasome and caspase substrates, rabbit polyclonal anti-ubiquitin, mouse monoclonal anti-&#946;-tubulin, and all cell culture reagents were obtained from Sigma.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/></s>
        <s sid="29">Lipofectamine 2000 and JC-1 (5,5&#8242;, 6,6&#8242;-tetrachloro-1,1&#8242;,3,3&#8242;-tetraethylbenzimidazolocarbocyanine iodide) were purchased from <xref class="inline-ad-match" href="/cgi/redirect-inline?ad=Invitrogen" rel="external-nw">Invitrogen</xref> and <xref class="inline-ad-match" href="/cgi/redirect-inline?ad=Molecular%20Probes" rel="external-nw">Molecular Probes</xref>, respectively.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/></s>
        <s sid="30">Dual luciferase reporter gene assay kit was purchased from Promega.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp3" novelty="None" advantage="None"/></s>
        <s sid="31">Mouse monoclonal anti-GFP and anti-HA were from Roche Applied Science; mouse monoclonal anti-cytochrome c and anti-p27<sup>kip1</sup> were from Pharmingen; and mouse monoclonal anti-I&#954;B kinase-&#946; (IKK&#946;), rabbit polyclonal anti-I&#954;B-&#945;, anti-phospho-I&#954;B-&#945;, anti-Bax, and anti-p53 were from Santa Cruz Biotechnology.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp4" novelty="None" advantage="None"/></s>
        <s sid="32">Goat anti-rabbit IgG-fluorescein isothiocyanate was purchased from Vector laboratories, and horseradish peroxidase-conjugated anti-mouse and anti-rabbit IgG were from Amersham Biosciences.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp5" novelty="None" advantage="None"/></s>
        <s sid="33">The source of plasmids ubiquitin (with HA tag), pd1EGFP-N1, Hsp70, and Hsp40 are described elsewhere (<xref class="xref-ref" href="#ref-29" rid="xref-ref-29-1">29</xref>, <xref class="xref-ref" href="#ref-35" rid="xref-ref-35-1">35</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp6" novelty="None" advantage="None"/></s>
        <s sid="34">I&#954;B-&#945;-EGFP plasmid was purchased from BD Biosciences.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp7" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-8">
        <s sid="35">Cell Culture, Treatments, and Viability Assay&#8212;Neuro 2a, COS-1, and HeLa cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum and penicillin/streptomycin antibiotics.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp8" novelty="None" advantage="None"/></s>
        <s sid="36">For routine experiments, the cells were plated onto a 6-well tissue culture plate at subconfluent density.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp9" novelty="None" advantage="None"/></s>
        <s sid="37">After 24 h of plating, cells were treated with different doses of aspirin and MG132 for different time periods and then processed for immunoblotting experiments.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp10" novelty="None" advantage="None"/></s>
        <s sid="38">For cell viability assay, cells (5 &#215; 10<sup>3</sup> cells/well) were seeded into 96-well plates, and 24 h after seeding, medium was replaced and cells were treated with different doses of aspirin alone or along with NAC.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp11" novelty="None" advantage="None"/></s>
        <s sid="39">In some experiments, the cells were plated onto 48-well tissue culture plates.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp12" novelty="None" advantage="None"/></s>
        <s sid="40">On the following day, cells were transfected with Hsp40 and Hsp70 plasmids.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp13" novelty="None" advantage="None"/></s>
        <s sid="41">Twenty-four hours later, cells were treated with different doses of aspirin and then processed for cell viability assay.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp14" novelty="None" advantage="None"/></s>
        <s sid="42">Cell viability was measured by MTT assay and trypan blue dye exclusion method.<CoreSc1 atype="GSC" type="Met" conceptID="Met1" novelty="None" advantage="None"/></s>
        <s sid="43">Statistical analysis was performed using Student's t test, and p &lt; 0.05 was considered to indicate statistical significance.<CoreSc1 atype="GSC" type="Met" conceptID="Met2" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-9">
        <s sid="44">Co-immunoprecipitation and Immunoblotting Experiment&#8212;Twenty-four hours after transfection of pd1EGFP plasmids, cells were treated with different doses of aspirin and MG132 for 8 h.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp15" novelty="None" advantage="None"/></s>
        <s sid="45">Cells were then washed with cold PBS, scraped, pelleted by centrifugation, and lysed on ice for 30 min with Nonidet P-40 lysis buffer (50 m<span class="sc">m</span> Tris, pH 8.0, 150 m<span class="sc">m</span> NaCl, 1% Nonidet P-40, complete protease inhibitor mixture).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp16" novelty="None" advantage="None"/></s>
        <s sid="46">Cell lysates were briefly sonicated, centrifuged for 10 min at 15000 &#215; g at 4 &#176;C, and the supernatants (total soluble extract) were used for immunoprecipitation.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp17" novelty="None" advantage="None"/></s>
        <s sid="47">Protein concentration was measured according to the method of Bradford using bovine serum albumin as a standard (<xref class="xref-ref" href="#ref-36" rid="xref-ref-36-1">36</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp18" novelty="None" advantage="None"/></s>
        <s sid="48">For each immunoprecipitation experiment, 200-&#956;g protein in 0.2 ml of Nonidet P-40 lysis buffer was incubated with 5 &#956;l (2.5 &#956;g) of GFP antibody.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp19" novelty="None" advantage="None"/></s>
        <s sid="49">After overnight incubation at 4 &#176;C with rotation, 20 &#956;l of protein G-agarose beads were added, and incubation was continued at 4 &#176;C for 5 h.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp20" novelty="None" advantage="None"/></s>
        <s sid="50">The beads were washed six times with Nonidet P-40 lysis buffer.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp21" novelty="None" advantage="None"/></s>
        <s sid="51">Bound proteins were eluted from the beads with SDS (1&#215;) sample buffer, vortexed, boiled for 5 min, and analyzed by immunoblotting.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp22" novelty="None" advantage="None"/></s>
        <s sid="52">The total cell lysate or the immunoprecipitated proteins were separated through SDS-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp23" novelty="None" advantage="None"/></s>
        <s sid="53">The membranes were successively incubated in blocking buffer (5% skim milk in TBST (50 m<span class="sc">m</span> Tris, pH 7.5, 0.15 <span class="sc">m</span> NaCl, 0.05% Tween)) with primary antibody in TBST and then with secondary antibody conjugated with horseradish peroxidase in TBST.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp24" novelty="None" advantage="None"/></s>
        <s sid="54">Detection was carried out with enhanced chemiluminescence reagent.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp25" novelty="None" advantage="None"/></s>
        <s sid="55">All primary antibodies were used in 1:1000 dilutions for immunoblotting.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp26" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-10">
        <s sid="56">In Vitro Kinase Assay&#8212;Neuro 2a cells were transiently transfected with the I&#954;B-&#945;-EGFP plasmid, and 24 h later the cells were collected and lysed in 400 &#956;l of buffer A (20 m<span class="sc">m</span> Tris-HCl, pH 7.5, 1% Triton X-100, 0.5% deoxycholate, 5 m<span class="sc">m</span> EGTA, 150 m<span class="sc">m</span> NaCl, 10 m<span class="sc">m</span> NaF, 1 m<span class="sc">m</span> dithiothreitol, 1 m<span class="sc">m</span> sodium orthovanadate, and complete protease inhibitor mixture).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp27" novelty="None" advantage="None"/></s>
        <s sid="57">Cell lysates were immunoprecipitated with IKK&#946; and GFP antibodies.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp28" novelty="None" advantage="None"/></s>
        <s sid="58">Immune complex was washed twice with buffer A and then equal amounts of immunoprecipitated proteins were incubated with or without different doses of aspirin for 30 min at 4 &#176;C, and in vitro kinase assay was performed at 30 &#176;C for 30 min as described elsewhere (<xref class="xref-ref" href="#ref-37" rid="xref-ref-37-1">37</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp29" novelty="None" advantage="None"/></s>
        <s sid="59">The samples were then subjected to immunoblotting using phospho-I&#954;B-&#945; and IKK&#946; antibodies.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp30" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-11">
        <s sid="60">Measurement of Mitochondrial Membrane Potential and Cytochrome c Release&#8212;Neuro 2a cells were plated onto a 60-mm tissue culture plate at subconfluent density.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp31" novelty="None" advantage="None"/></s>
        <s sid="61">Twenty-four hours later, cells were exposed to different doses of aspirin and MG132 for 12 h and then incubated with 5 &#956;<span class="sc">m</span> JC-1 fluorescence dye for 30 min in the CO<sub>2</sub> incubator and washed several times with PBS prewarmed at 37 &#176;C.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp32" novelty="None" advantage="None"/></s>
        <s sid="62">Mitochondrial membrane potential was evaluated qualitatively under a fluorescence microscope using 568-nm filter.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp33" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-12">
        <s sid="63">To study the release of cytochrome c from mitochondria, Neuro 2a cells grown on chamber slides were treated with different doses of aspirin and MG132.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa1" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Exp" conceptID="Exp34" novelty="None" advantage="None"/></s>
        <s sid="64">Twelve h after treatment, cells were washed twice with PBS, fixed with 4% paraformaldehyde in PBS for 20 min, permeabilized with 0.5% Triton X-100 in PBS for 5 min, washed extensively and then blocked with 5% nonfat dried milk in TBST for 1 h.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp35" novelty="None" advantage="None"/></s>
        <s sid="65">Primary antibody (anti-cytochrome c) incubation was carried out overnight at 4 &#176;C.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp36" novelty="None" advantage="None"/></s>
        <s sid="66">After several washings with TBST, cells were incubated with fluorescein isothiocyanate-conjugated secondary antibody for 4 h, washed several times, and visualized using a fluorescence microscope.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp37" novelty="None" advantage="None"/></s>
        <s sid="67">The digital images were assembled using Adobe Photoshop.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp38" novelty="None" advantage="None"/></s>
        <s sid="68">To evaluate the release of cytochrome c from mitochondria by immunoblotting, Neuro 2a cells were grown on tissue culture dishes, and the cells were then treated with different doses of aspirin for 12 h.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa2" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Exp" conceptID="Exp39" novelty="None" advantage="None"/></s>
        <s sid="69">The cells were collected by scraping, washed in the PBS followed by sucrose buffer (20 m<span class="sc">m</span> HEPES, pH 7.5, 10 m<span class="sc">m</span> KCl, 1.5 m<span class="sc">m</span> MgCl<sub>2</sub>, 1 m<span class="sc">m</span> EDTA, 1 m<span class="sc">m</span> EGTA, 1 m<span class="sc">m</span> dithiothreitol, and 0.1 m<span class="sc">m</span> phenylmethylsulfonyl fluoride containing 250 m<span class="sc">m</span> sucrose), and resuspended in the same buffer.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp40" novelty="None" advantage="None"/></s>
        <s sid="70">After 1 h of incubation on ice, cells were lysed by Dounce homogenizer of B-type pestle with 30 strokes.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp41" novelty="None" advantage="None"/></s>
        <s sid="71">Homogenates were centrifuged at 750 &#215; g for 10 min at 4 &#176;C, and the supernatants were recentrifuged at 10,000 &#215; g for 15 min at 4 &#176;C.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp42" novelty="None" advantage="None"/></s>
        <s sid="72">The final supernatants were used for immunoblotting experiments of cytochrome c.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp43" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-13">
        <s sid="73">Assay of Proteasome, and Caspase-9- and Caspase-3-like Protease Activity&#8212;The cells were plated onto a 6-well tissue culture plate, and on the following day, cells were treated with varying doses of aspirin and MG132 for different time periods.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp44" novelty="None" advantage="None"/></s>
        <s sid="74">Cells were then isolated and processed for proteasome activity assay as described earlier (<xref class="xref-ref" href="#ref-29" rid="xref-ref-29-2">29</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met3" novelty="None" advantage="None"/></s>
        <s sid="75">The substrates Succinyl-Leu-Leu-Val-Tyr-MCA and benzyloxycarbonyl-Leu-Leu-Glu-MCA were used to determine chymotrypsin and post-glutamyl peptidyl hydrolytic-like activity, respectively.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp45" novelty="None" advantage="None"/></s>
        <s sid="76">To evaluate the direct effect of aspirin on the protease activity of proteasome, pure 20 S proteasome (250 ng/reaction) was used instead of cell supernatant in the protease activity assay buffer.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa3" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Exp" conceptID="Exp46" novelty="None" advantage="None"/></s>
        <s sid="77">Protease activities at a particular time point (30 min) within the linear range were used to calculate the data.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp47" novelty="None" advantage="None"/></s>
        <s sid="78">The fluorescence intensity was measured at 380 nm excitation and 460 nm emissions using a fluorescence plate reader.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp48" novelty="None" advantage="None"/></s>
        <s sid="79">The caspase-9- and -3-like protease activities were determined as described earlier (<xref class="xref-ref" href="#ref-32" rid="xref-ref-32-2">32</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met4" novelty="None" advantage="None"/></s>
        <s sid="80">The substrates Ac-Asp-Glu-Val-Asp-MCA and Ac-Leu-Glu-His-Asp-MCA were used to determine the caspase-3- and -9-like protease activity, respectively.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp49" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-14"/>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-16"/>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-18">
        <s sid="81">Cycloheximide-Chase Experiment&#8212;Neuro 2a cells were plated onto a 6-well tissue culture plate and on the following day, cells were chased with 15 &#956;g/ml of cycloheximide for different time periods in the presence or absence of aspirin.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp50" novelty="None" advantage="None"/></s>
        <s sid="82">Cells collected at each time point were then processed for immunoblotting using antibodies against Bax, I&#954;B-&#945;, p53, p27<sup>kip1</sup>, and &#946;-tubulin.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp51" novelty="None" advantage="None"/></s>
        <s sid="83">In some experiments, Neuro 2a cells were transiently transfected with pd1EGFP plasmids, and 24 h later, cells were chased with cycloheximide as described above.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp52" novelty="None" advantage="None"/></s>
        <s sid="84">The collected cells at each time points were then processed for immunoblotting using anti-GFP.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp53" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-19">
        <s sid="85">Reporter Gene Assay&#8212;Neuro 2a cells were plated onto 6-well tissue culture plates at a subconfluent density.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp54" novelty="None" advantage="None"/></s>
        <s sid="86">Twenty-four hours later, cells were transiently transfected with NF-&#954;B-luciferase and pRL-SV40 plasmids together using Lipofectamine 2000 reagent according to the manufacturer's instructions.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp55" novelty="None" advantage="None"/></s>
        <s sid="87">Transfection efficiency was about 80-90%.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp56" novelty="None" advantage="None"/></s>
        <s sid="88">Twenty-four hours posttransfection, cells were treated with different doses of aspirin and then processed for luciferase assay.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp57" novelty="None" advantage="None"/></s>
        <s sid="89">Luciferase activity was measured using a dual luciferase reporter assay system according to the manufacturer's instructions.<CoreSc1 atype="GSC" type="Met" conceptID="Met5" novelty="None" advantage="None"/></s>
        <s sid="90">pRL-SV40 plasmid was used for co-transfection to normalize the data, and it was transfected at avery low concentration (150-fold lower than NF-&#954;B luciferase plasmid).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp58" novelty="None" advantage="None"/></s>
        <s sid="91">The data were represented as relative luciferase activity (the ratio of firefly to Renilla values).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp59" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>RESULTS</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-20">
        <s sid="92">Aspirin Inhibits Growth and Induces Apoptosis in Neuro 2a Cells&#8212;Aspirin and other NSAIDs have been found to induce apoptosis in many cell types.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac17" novelty="None" advantage="None"/></s>
        <s sid="93">Here we first tested the effect of aspirin on the viability of mouse Neuro 2a neuroblastoma cells.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj2" novelty="None" advantage="None"/></s>
        <s sid="94">The cells were plated onto 96-well tissue culture plates, and on the following day, the cells were exposed to the different doses of aspirin for 24 h.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp60" novelty="None" advantage="None"/></s>
        <s sid="95">The cell viability was determined by MTT assay.<CoreSc1 atype="GSC" type="Met" conceptID="Met6" novelty="None" advantage="None"/></s>
        <s sid="96">As shown in <xref class="xref-" href="#F1" rid="xref-fig-1-1">Fig. 1</xref>, treatment with aspirin dose dependently reduced the cell viability.<CoreSc1 atype="GSC" type="Res" conceptID="Res5" novelty="None" advantage="None"/></s>
        <s sid="97">Aspirin at a dose of 2.5 m<span class="sc">m</span> (the concentration that can be found in the serum of patients treated with aspirin for chronic inflammatory diseases (<xref class="xref-ref" href="#ref-38" rid="xref-ref-38-1">38</xref>)) significantly increased the cell death to about 15 and 35% after 24 and 48 h of exposure, respectively, but how aspirin induced the cell death program was not very clear.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot3" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Res" conceptID="Res6" novelty="None" advantage="None"/></s>
        <s sid="98">NSAIDs have been found to induce the expression of heat shock proteins (Hsps) and generate the oxidative and ER stress (<xref class="xref-ref" href="#ref-21" rid="xref-ref-21-2">21</xref>, <xref class="xref-ref" href="#ref-22" rid="xref-ref-22-2">22</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac18" novelty="None" advantage="None"/></s>
        <s sid="99">Therefore, we presumed that aspirin-induced apoptosis might be because of the induction of stress responses.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp3" novelty="None" advantage="None"/></s>
        <s sid="100">To test this hypothesis, we checked the role of antioxidant NAC and the overexpression of various heat shock proteins on aspirin-induced cell death.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa4" novelty="None" advantage="None"/></s>
        <s sid="101">The treatment of NAC dose dependently rescued aspirin-induced cell death (<xref class="xref-" href="#F1" rid="xref-fig-1-2">Fig. 1B</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res7" novelty="None" advantage="None"/></s>
        <s sid="102">Aspirin-induced cell death was also prevented upon overexpression of Hsp70 and Hsp40 chaperones (<xref class="xref-" href="#F1" rid="xref-fig-1-3">Fig. 1C</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res8" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-21"/>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-23"/>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-25">
        <s sid="103">Aspirin Inhibits the Proteasome Function&#8212;We next tried to explore the mechanism of aspirin-induced stress responses in the cells.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa5" novelty="None" advantage="None"/></s>
        <s sid="104">Because the inhibition of proteasomal function induces the stress responses inside the cells, we checked the possible role of aspirin on proteasomal dysfunction.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj3" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Mot" conceptID="Mot4" novelty="None" advantage="None"/></s>
        <s sid="105">As shown in <xref class="xref-" href="#F2" rid="xref-fig-2-1">Fig. 2, A and B</xref>, dose and time dependently, aspirin treatment of Neuro 2a cells inhibits various protease activities of proteasome.<CoreSc1 atype="GSC" type="Res" conceptID="Res9" novelty="None" advantage="None"/></s>
        <s sid="106">Aspirin exposure at doses of 2.5, 5, and 10 m<span class="sc">m</span> for 8 h caused about 25, 40, and 60% inhibition of proteasome activity, respectively.<CoreSc1 atype="GSC" type="Res" conceptID="Res10" novelty="None" advantage="None"/></s>
        <s sid="107">Aspirin also inhibited the proteasome activity in HeLa and COS-1 cells (<xref class="xref-" href="#F2" rid="xref-fig-2-2">Fig. 2C</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res11" novelty="None" advantage="None"/></s>
        <s sid="108">In many experiments, we used 10 m<span class="sc">m</span> aspirin to reduce the time of exposure.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp61" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-26">
        <s sid="109">Because aspirin inhibits the proteasome activity in cell culture, we were further interested to know the possible mechanism of proteasome inhibition.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa6" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Mot" conceptID="Mot5" novelty="None" advantage="None"/></s>
        <s sid="110">Therefore, we tested the direct effect of aspirin on proteasome activity.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj4" novelty="None" advantage="None"/></s>
        <s sid="111">The partially purified 20 S proteasome was incubated with varying doses of aspirin in the presence of chymotrypsin-like protease substrate.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp62" novelty="None" advantage="None"/></s>
        <s sid="112"><xref class="xref-" href="#F2" rid="xref-fig-2-3">Fig. 2D</xref> shows that aspirin had no effect on the protease activity of the purified 20 S proteasome.<CoreSc1 atype="GSC" type="Res" conceptID="Res12" novelty="None" advantage="None"/></s>
        <s sid="113">Proteasome inhibitors MG132 and lactacystin were used as positive controls, and they dramatically decreased the proteasome activity.<CoreSc1 atype="GSC" type="Res" conceptID="Res13" novelty="None" advantage="None"/></s>
        <s sid="114">Thus our results suggest that aspirin-induced proteasomal inhibition is mediated indirectly.<CoreSc1 atype="GSC" type="Con" conceptID="Con3" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-27">
        <s sid="115">To reconfirm the aspirin-induced proteasomal malfunction in cell culture, we checked the ubiquitylation profile because inhibition of proteasome function would lead to the increased accumulation of ubiquitylated derivatives of various proteins.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa7" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Bac" conceptID="Bac19" novelty="None" advantage="None"/><CoreSc3 atype="GSC" type="Exp" conceptID="Exp63" novelty="None" advantage="None"/></s>
        <s sid="116"><xref class="xref-" href="#F3" rid="xref-fig-3-1">Fig. 3</xref> shows that the exposure to aspirin caused a dose-dependent increase in the accumulation of ubiquitylated derivatives of various cellular proteins.<CoreSc1 atype="GSC" type="Res" conceptID="Res14" novelty="None" advantage="None"/></s>
        <s sid="117">To further confirm the accumulation of ubiquitylated proteins upon aspirin treatment, we transiently transfected Neuro 2a cells with HA-ubiquitin plasmids and then treated them with different doses of aspirin.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa8" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Exp" conceptID="Exp64" novelty="None" advantage="None"/></s>
        <s sid="118">The blot was detected with HA antibody.<CoreSc1 atype="GSC" type="Met" conceptID="Met7" novelty="None" advantage="None"/></s>
        <s sid="119">In this case, we also detected an increased accumulation of HA-tagged ubiquitylated proteins and a subsequent decrease in the free HA-tagged ubiquitin levels (<xref class="xref-" href="#F3" rid="xref-fig-3-2">Fig. 3B</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res15" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-28"/>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-30">
        <s sid="120">Aspirin Treatment Decreases the Turnover of a Model Substrate of Proteasome&#8212;Aspirin-induced proteasomal dysfunction was further confirmed by using destabilized enhanced green fluorescent protein (d1EGFP), a model substrate for proteasome with 1 h of half-life.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj5" novelty="None" advantage="None"/></s>
        <s sid="121">The pd1EGFP vector contains multiple proline, glutamic acid, serine, and threonine signal sequence in its C terminus, which can be targeted for degradation by proteasome.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac20" novelty="None" advantage="None"/></s>
        <s sid="122">The proteasomal malfunction will increase the half-life of this protein.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac21" novelty="None" advantage="None"/></s>
        <s sid="123">Neuro 2a cells were transiently transfected with the pd1EGFP expression plasmids, and then the cells were chased with cycloheximide in the presence or absence of 10 m<span class="sc">m</span> aspirin.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp65" novelty="None" advantage="None"/></s>
        <s sid="124">Results show that the treatment with 10 m<span class="sc">m</span> aspirin increased the half-life of d1EGFP proteins by about 3.5-fold (<xref class="xref-" href="#F4" rid="xref-fig-4-1">Fig. 4, A and B</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res16" novelty="None" advantage="None"/></s>
        <s sid="125">In another experiment, Neuro 2a cells were transiently transfected with pd1EGFP plasmids and then treated with varying doses of aspirin and MG132.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp66" novelty="None" advantage="None"/></s>
        <s sid="126">The cell lysates were then processed for co-immunoprecipitation experiment using anti-GFP, and the blot was detected sequentially with ubiquitin and GFP antibody.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp67" novelty="None" advantage="None"/></s>
        <s sid="127">As expected, aspirin treatment, like MG132, resulted in increased accumulations of ubiquitylated d1EGFP proteins (<xref class="xref-" href="#F4" rid="xref-fig-4-2">Fig. 4C</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res17" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-31">
        <s sid="128">Exposure to Aspirin Increases the Half-life of Various Cellular Substrates of Proteasome&#8212;Because aspirin increases the half-life of a model substrate of proteasome, we next tested its effect on the half-life of other cellular target substrates.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj6" novelty="None" advantage="None"/></s>
        <s sid="129">First, we checked the effect of aspirin on the accumulations and degradations of I&#954;B-&#945; and the down-regulation of NF-&#954;B activity.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj7" novelty="None" advantage="None"/></s>
        <s sid="130">As shown in <xref class="xref-" href="#F5" rid="xref-fig-5-1">Fig. 5, A-C</xref>, the treatment with aspirin caused a dose-dependent increase in accumulation and increased half-life of I&#954;B-&#945;.<CoreSc1 atype="GSC" type="Res" conceptID="Res18" novelty="None" advantage="None"/></s>
        <s sid="131">This increased half-life of I&#954;B-&#945; might be involved, at least in part, in the down-regulation of the NF-&#954;B-dependent transcriptional activity (<xref class="xref-" href="#F5" rid="xref-fig-5-2">Fig. 5D</xref>).<CoreSc1 atype="GSC" type="Con" conceptID="Con4" novelty="None" advantage="None"/></s>
        <s sid="132">Aspirin-induced increased accumulation of I&#954;B-&#945; is not only observed in Neuro 2a cells but also can be detected in COS-1 and HeLa cells (<xref class="xref-" href="#F5" rid="xref-fig-5-3">Fig. 5E</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res19" novelty="None" advantage="None"/></s>
        <s sid="133">Aspirin at a dose of 5 m<span class="sc">m</span> caused about 3-fold increase in the accumulation of I&#954;B-&#945; in COS-1 and HeLa cells.<CoreSc1 atype="GSC" type="Res" conceptID="Res20" novelty="None" advantage="None"/></s>
        <s sid="134">However, an earlier report demonstrated the enhanced degradation of I&#954;B-&#945; in aspirin-treated colon cancer cells (<xref class="xref-ref" href="#ref-39" rid="xref-ref-39-1">39</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac22" novelty="None" advantage="None"/></s>
        <s sid="135">Therefore, the effect of aspirin on I&#954;B-&#945; might be cell-specific.<CoreSc1 atype="GSC" type="Con" conceptID="Con5" novelty="None" advantage="None"/></s>
        <s sid="136">Interestingly, aspirin-induced NF-&#954;B inhibition was much more dramatic than the proteasomal inhibition.<CoreSc1 atype="GSC" type="Res" conceptID="Res21" novelty="None" advantage="None"/></s>
        <s sid="137">This suggests that proteasomal dysfunction is not the only reason for aspirin-induced NF-&#954;B inhibition.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp4" novelty="None" advantage="None"/></s>
        <s sid="138">In fact, earlier report demonstrated the specific inhibition of IKK&#946; induced by aspirin both in vitro and also in COS-1, HeLa, and LNCaP cells (<xref class="xref-ref" href="#ref-15" rid="xref-ref-15-2">15</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac23" novelty="None" advantage="None"/></s>
        <s sid="139">We have also found similar results in Neuro 2a cells (<xref class="xref-" href="#F5" rid="xref-fig-5-4">Fig. 5F</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res22" novelty="None" advantage="None"/></s>
        <s sid="140">Therefore, it is possible that aspirin-induced inhibition of IKK&#946; and proteasome activity both might be involved in the down-regulation of NF-&#954;B activity.<CoreSc1 atype="GSC" type="Con" conceptID="Con6" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-32">
        <s sid="141">Next, we checked the half-life of three other known substrates of proteasome, Bax, p53, and p27<sup>kip1</sup>.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj8" novelty="None" advantage="None"/></s>
        <s sid="142">As expected the half-life of Bax, p53, and p27<sup>kip1</sup> were dramatically increased upon treatment with aspirin (<xref class="xref-" href="#F6" rid="xref-fig-6-1">Fig. 6</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res23" novelty="None" advantage="None"/></s>
        <s sid="143">Aspirin at a dose of 10 m<span class="sc">m</span> increased the half-life of Bax, p53, and p27<sup>kip1</sup> by about 4-fold.<CoreSc1 atype="GSC" type="Res" conceptID="Res24" novelty="None" advantage="None"/></s>
        <s sid="144">The increased accumulation of Bax, p53, and p27<sup>kip1</sup> might result in the cell cycle arrest and apoptosis.<CoreSc1 atype="GSC" type="Con" conceptID="Con7" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-33"/>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-35"/>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-37">
        <s sid="145">Aspirin Induces Mitochondrial Membrane Depolarization, Cytochrome c Release, and Activation of Caspases&#8212;Because proteasomal inhibition induces the mitochondrial pathway of apoptosis, we next checked the effect of aspirin on the mitochondrial membrane depolarization and cytochrome c release.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj9" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Mot" conceptID="Mot6" novelty="None" advantage="None"/></s>
        <s sid="146">Neuro 2a cells were exposed to different doses of aspirin for different time periods and then subjected to JC-1 staining to study the changes in the mitochondrial membrane potential or processed for immunofluorescence staining of cytochrome c.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp68" novelty="None" advantage="None"/></s>
        <s sid="147">JC-1 is a voltage-sensitive fluorescence dye that specifically detects the polarized mitochondria as red, and the depolarized membrane becomes green.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac24" novelty="None" advantage="None"/></s>
        <s sid="148">The treatment with aspirin dose dependently decreased the mitochondrial membrane potential as evident from the loss of red-dotted mitochondrial staining (<xref class="xref-" href="#F7" rid="xref-fig-7-1">Fig. 7</xref>, top panel).<CoreSc1 atype="GSC" type="Res" conceptID="Res25" novelty="None" advantage="None"/></s>
        <s sid="149">Aspirin treatment also dose dependently induced the cytochrome c release from the mitochondria (<xref class="xref-" href="#F7" rid="xref-fig-7-2">Fig. 7</xref>, bottom panel, and <xref class="xref-" href="#F8" rid="xref-fig-8-1">Fig. 8A</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs1" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-38">
        <s sid="150">Because the caspase-9 activation is initiated with the release of cytochrome c from mitochondria followed by binding to apoptosis protease-activating factor-1, we further examined the activation of caspase-9 and subsequent events upon aspirin treatment.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj10" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Mot" conceptID="Mot7" novelty="None" advantage="None"/></s>
        <s sid="151">As shown in <xref class="xref-" href="#F8" rid="xref-fig-8-2">Fig. 8B</xref>, aspirin exposure dose dependently increased the activity of both caspase-9 and -3.<CoreSc1 atype="GSC" type="Res" conceptID="Res26" novelty="None" advantage="None"/></s>
        <s sid="152">The MG132 was used as a positive control.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp69" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-39">
        <s sid="153">Treatment with Aspirin Induces Neurite Outgrowth&#8212;The impairment of proteasome function is also known to induce the neurite outgrowth.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac25" novelty="None" advantage="None"/></s>
        <s sid="154">Because aspirin inhibits the proteasome function, we further tested its possible effect on neurite out-growth.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj11" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Mot" conceptID="Mot8" novelty="None" advantage="None"/></s>
        <s sid="155">As shown in <xref class="xref-" href="#F9" rid="xref-fig-9-1">Fig. 9</xref>, aspirin exposure induced the neurite outgrowth like proteasome inhibitor, MG132, depending upon the dose.<CoreSc1 atype="GSC" type="Res" conceptID="Res27" novelty="None" advantage="None"/></s>
        <s sid="156">Approximately 50% of the cells looked bipolar (having two neurites), and the rest were round at a 10 m<span class="sc">m</span> dose.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs2" novelty="None" advantage="None"/></s>
        <s sid="157">Aspirin-induced neurite outgrowth could be because of the increased accumulation of p27<sup>kip1</sup> or ubiquitylated proteins.<CoreSc1 atype="GSC" type="Con" conceptID="Con8" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>DISCUSSION</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-40">
        <s sid="158">Apart from the classical anti-inflammatory function, aspirin and other NSAIDs exhibit an antiproliferative effect because of their ability to induce apoptosis on a variety of cancer cells (<xref class="xref-ref" href="#ref-7" rid="xref-ref-7-2">7</xref>-<xref class="xref-ref" href="#ref-14" rid="xref-ref-14-6">14</xref>), but how they induce apoptosis is not well understood.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot9" novelty="None" advantage="None"/></s>
        <s sid="159">Here we report that aspirin inhibits the proteasome function and causes severe mitochondrial abnormalities.<CoreSc1 atype="GSC" type="Res" conceptID="Res28" novelty="None" advantage="None"/></s>
        <s sid="160">This inhibition of proteasome function by aspirin play an important role in the induction of apoptotic signals and anti-inflammatory responses.<CoreSc1 atype="GSC" type="Con" conceptID="Con9" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-41"/>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-43"/>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-45">
        <s sid="161">Firstly, we have shown that the exposure to aspirin dose and time dependently inhibits the cellular proteasome function and increases the accumulations of ubiquitylated derivatives of various cellular proteins.<CoreSc1 atype="GSC" type="Res" conceptID="Res29" novelty="None" advantage="None"/></s>
        <s sid="162">The inhibition of proteasome function induced by aspirin correlates well with its effect on cell death.<CoreSc1 atype="GSC" type="Res" conceptID="Res30" novelty="None" advantage="None"/></s>
        <s sid="163">Secondly, we have found that treatment with aspirin inhibits the degradation of destabilized enhanced green fluorescence proteins and also various other cellular substrates of proteasome like Bax, I&#954;B-&#945;, p53, and p27<sup>kip1</sup>.<CoreSc1 atype="GSC" type="Res" conceptID="Res31" novelty="None" advantage="None"/></s>
        <s sid="164">Finally, we have demonstrated the dramatic changes of mitochondrial membrane potential, release of cytochrome c from mitochondria into cytosol, and activation of caspase-9 and -3 upon aspirin exposure, which might be because of the proteasomal malfunction.<CoreSc1 atype="GSC" type="Con" conceptID="Con10" novelty="None" advantage="None"/></s>
        <s sid="165">The dose of aspirin (1-5 m<span class="sc">m</span>) we used can be measured in the serum of patients treated with aspirin for various chronic inflammatory diseases (<xref class="xref-ref" href="#ref-38" rid="xref-ref-38-2">38</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac26" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-46">
        <s sid="166">The released cytochrome c into the cytosol binds with the apoptosis protease-activating factor-1 and forms the apoptosome complex, which in turn leads to the sequential activation of caspase-9 and -3.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac27" novelty="None" advantage="None"/></s>
        <s sid="167">In fact, aspirin, like other proteasome inhibitors, has been reported to activate caspase-9 and -3 by inducing the release of mitochondrial cytochrome c (<xref class="xref-ref" href="#ref-10" rid="xref-ref-10-2">10</xref>-<xref class="xref-ref" href="#ref-12" rid="xref-ref-12-2">12</xref>, <xref class="xref-ref" href="#ref-40" rid="xref-ref-40-1">40</xref>, <xref class="xref-ref" href="#ref-41" rid="xref-ref-41-1">41</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac28" novelty="None" advantage="None"/></s>
        <s sid="168">Aspirin, like other proteasome inhibitors, also induces the extrinsic pathway of caspase activation (<xref class="xref-ref" href="#ref-14" rid="xref-ref-14-7">14</xref>, <xref class="xref-ref" href="#ref-40" rid="xref-ref-40-2">40</xref>, <xref class="xref-ref" href="#ref-41" rid="xref-ref-41-2">41</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac29" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-47">
        <s sid="169">How can aspirin induce mitochondrial cytochrome c release?<CoreSc1 atype="GSC" type="Mot" conceptID="Mot10" novelty="None" advantage="None"/></s>
        <s sid="170">Aspirin is reported to up-regulate the expression of Bax (<xref class="xref-ref" href="#ref-11" rid="xref-ref-11-4">11</xref>, <xref class="xref-ref" href="#ref-14" rid="xref-ref-14-8">14</xref>), which can then translocate from cytosol to the outer mitochondrial membrane and make pores in the mitochondrial membrane to leak cytochrome c.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac30" novelty="None" advantage="None"/></s>
        <s sid="171">Bax is a substrate of proteasome, and its expression is induced by p53, which is also a substrate of proteasome.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac31" novelty="None" advantage="None"/></s>
        <s sid="172">Therefore, aspirin-induced proteasomal dys-function could conceivably cause mitochondrial cytochrome c release by up-regulating Bax and p53 levels because aspirin treatment causes up-regulation of these proteins (<xref class="xref-ref" href="#ref-8" rid="xref-ref-8-2">8</xref>, <xref class="xref-ref" href="#ref-11" rid="xref-ref-11-5">11</xref>, <xref class="xref-ref" href="#ref-14" rid="xref-ref-14-9">14</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac32" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-48">
        <s sid="173">Besides Bax and p53, there are several other proteins involved in regulating transcription; growth and apoptosis are substrates of proteasome.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac33" novelty="None" advantage="None"/></s>
        <s sid="174">Proteasome inhibition also up-regulates the expression of various proteins implicated in the pro-apoptotic pathway and down-regulates various transcripts involved in cell growth and survival pathways (<xref class="xref-ref" href="#ref-40" rid="xref-ref-40-3">40</xref>, <xref class="xref-ref" href="#ref-41" rid="xref-ref-41-3">41</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac34" novelty="None" advantage="None"/></s>
        <s sid="175">The altered degradation or altered expression of those proteins will definitely affect cell survival and promote apoptosis.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac35" novelty="None" advantage="None"/></s>
        <s sid="176">Here we have shown that treatment with aspirin leads to an increase in the half-life of Bax, p53, p27<sup>kip1</sup>, and I&#954;B-&#945; because of the impaired proteasome function.<CoreSc1 atype="GSC" type="Res" conceptID="Res32" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-49">
        <s sid="177">Aspirin-induced proteasomal dysfunction could explain several earlier reported effects of aspirin including inhibition of NF-&#954;B activity, cell cycle arrest, and induction of stress response (<xref class="xref-ref" href="#ref-7" rid="xref-ref-7-3">7</xref>-<xref class="xref-ref" href="#ref-9" rid="xref-ref-9-1">9</xref>, <xref class="xref-ref" href="#ref-15" rid="xref-ref-15-3">15</xref>-<xref class="xref-ref" href="#ref-17" rid="xref-ref-17-2">17</xref>, <xref class="xref-ref" href="#ref-21" rid="xref-ref-21-3">21</xref>, <xref class="xref-ref" href="#ref-22" rid="xref-ref-22-3">22</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac36" novelty="None" advantage="None"/></s>
        <s sid="178">All these effects can be observed during proteasomal inhibition.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac37" novelty="None" advantage="None"/></s>
        <s sid="179">Aspirin is known to inhibit the NF-&#954;B pathway, which is involved in the pathogenesis of inflammatory responses.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac38" novelty="None" advantage="None"/></s>
        <s sid="180">Earlier reports have demonstrated that aspirin inhibits the NF-&#954;B pathway by inhibiting the IKK&#946; (<xref class="xref-ref" href="#ref-15" rid="xref-ref-15-4">15</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac39" novelty="None" advantage="None"/></s>
        <s sid="181">Here we provide additional evidence that aspirin-induced proteasomal dysfunction prevents the degradation of I&#954;B-&#945; and thereby blocks the nuclear translocation and transactivation of NF-&#954;B.<CoreSc1 atype="GSC" type="Res" conceptID="Res33" novelty="None" advantage="None"/></s>
        <s sid="182">We have also found that aspirin, like other proteasome inhibitors, increases the accumulation of p27<sup>kip1</sup>.<CoreSc1 atype="GSC" type="Res" conceptID="Res34" novelty="None" advantage="None"/></s>
        <s sid="183">p27<sup>kip1</sup> acts as an inhibitor of cdk2 and cdk4 and is highly regulated by UPS.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac40" novelty="None" advantage="None"/></s>
        <s sid="184">Increased accumulation of p27<sup>kip1</sup> results in cell cycle arrest at the G<sub>1</sub>/S phase and apoptosis (<xref class="xref-ref" href="#ref-42" rid="xref-ref-42-1">42</xref>, <xref class="xref-ref" href="#ref-43" rid="xref-ref-43-1">43</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac41" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-50">
        <s sid="185">How does aspirin disturb the cellular proteasome function?<CoreSc1 atype="GSC" type="Mot" conceptID="Mot11" novelty="None" advantage="None"/></s>
        <s sid="186">It does not inhibit the proteasome function by directly inhibiting the enzyme activity.<CoreSc1 atype="GSC" type="Con" conceptID="Con11" novelty="None" advantage="None"/></s>
        <s sid="187">However, aspirin could impair the proteasome function indirectly by inhibiting the expression of various subunits of proteasome.<CoreSc1 atype="GSC" type="Con" conceptID="Con12" novelty="None" advantage="None"/></s>
        <s sid="188">Oxidative and ER stress can also promote aspirin-induced proteasomal malfunction because aspirin treatment generates oxidative and ER stress, and both of them have been reported to induce the proteasomal malfunction (<xref class="xref-ref" href="#ref-33" rid="xref-ref-33-2">33</xref>, <xref class="xref-ref" href="#ref-44" rid="xref-ref-44-1">44</xref>, <xref class="xref-ref" href="#ref-45" rid="xref-ref-45-1">45</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac42" novelty="None" advantage="None"/></s>
        <s sid="189">Aspirin-induced mitochondrial damage would be able to generate the oxidative stress inside the cell (<xref class="xref-ref" href="#ref-12" rid="xref-ref-12-3">12</xref>-<xref class="xref-ref" href="#ref-14" rid="xref-ref-14-10">14</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac43" novelty="None" advantage="None"/></s>
        <s sid="190">Oxidative stress can again damage mitochondria and thus generate a vicious cycle.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac44" novelty="None" advantage="None"/></s>
        <s sid="191">Oxidative stress would be able to disturb the proteasome function either by producing excessive levels of damaged protein or by reducing the levels of ATP production.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac45" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-51">
        <s sid="192">Altogether, our results suggest that aspirin inhibits the proteasome function, and the impairment of proteasome function might be associated at least in part with its anti-inflammatory function as well as the induction of apoptosis.<CoreSc1 atype="GSC" type="Con" conceptID="Con13" novelty="None" advantage="None"/></s>
        <s sid="193">Proteasome inhibitors are considered to be promising anticancer agents, and recently the Food and Drug Administration approved the first proteasome inhibitor, bortezomib (Velcade), for the treatment of multiple myeloma (<xref class="xref-ref" href="#ref-46" rid="xref-ref-46-1">46</xref>, <xref class="xref-ref" href="#ref-47" rid="xref-ref-47-1">47</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac46" novelty="None" advantage="None"/></s>
        <s sid="194">Therefore, aspirin has enormous potential in the prevention and therapy of cancer apart from its popular use as an anti-inflammatory drug.<CoreSc1 atype="GSC" type="Con" conceptID="Con14" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Acknowledgments</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-54">
        <s sid="195">We are grateful to Dr. Anirban Basu of our institute for providing the Bax antibody.</s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Footnotes</TITLE>
    </SEC>
    <SEC>
      <TITLE>References</TITLE>
    </SEC>
  </BODY>
</PAPER>